Edward Tenthoff
Stock Analyst at Piper Sandler
(3.28)
# 968
Out of 5,182 analysts
198
Total ratings
39.47%
Success rate
3.79%
Average return
Main Sectors:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics | Reiterates: Overweight | $12 → $8 | $5.89 | +35.82% | 2 | Mar 30, 2026 | |
| GENB Generate Biomedicines | Initiates: Overweight | $24 | $13.75 | +74.55% | 1 | Mar 24, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 → $110 | $49.51 | +122.18% | 8 | Mar 17, 2026 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $45 → $58 | $32.11 | +80.63% | 3 | Mar 13, 2026 | |
| IBRX ImmunityBio | Reiterates: Overweight | $7 → $12 | $7.30 | +64.38% | 1 | Mar 4, 2026 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $10 → $6 | $1.58 | +279.75% | 1 | Feb 25, 2026 | |
| ARVN Arvinas | Reiterates: Overweight | $16 → $20 | $10.85 | +84.33% | 8 | Feb 25, 2026 | |
| MRNA Moderna | Maintains: Overweight | $63 → $69 | $49.20 | +40.24% | 14 | Feb 23, 2026 | |
| IPSC Century Therapeutics | Maintains: Overweight | $2 → $4 | $2.13 | +87.79% | 9 | Jan 20, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Overweight | $28 → $37 | $17.09 | +116.50% | 4 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 → $110 | $61.03 | +80.24% | 14 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $1.52 | +426.32% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $98 → $125 | $85.40 | +46.37% | 5 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 → $23 | $8.04 | +186.07% | 6 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 → $6 | $1.13 | +430.97% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $449 → $489 | $318.85 | +53.36% | 15 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $12 | $4.47 | +168.46% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $15 | $10.72 | +39.93% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 | $23.78 | -15.90% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.54 | +354.55% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $18.84 | +154.78% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $14.81 | +62.05% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $19.14 | +307.52% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $12.81 | +134.19% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $1.59 | +3,988.05% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $0.70 | +2,765.33% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.14 | +163.16% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.18 | +1,567.59% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.22 | +391.80% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.38 | +262.32% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $4.24 | +2,022.64% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $9.27 | +1,841.75% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $15.51 | +183.69% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $5.05 | +632.67% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40,439,520 → $11,721,600 | $4.17 | +281,093,425.18% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $746.75 | -52.59% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $438.71 | -26.38% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $25 | $10.20 | +145.10% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $43.88 | -17.96% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.32 | +1,793.94% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.55 | +27,347.39% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13,800 | $0.36 | +3,877,393.68% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $761.85 | - | 11 | Feb 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $882 → $1,064 | $11.87 | +8,863.77% | 2 | Apr 15, 2013 |
Karyopharm Therapeutics
Mar 30, 2026
Reiterates: Overweight
Price Target: $12 → $8
Current: $5.89
Upside: +35.82%
Generate Biomedicines
Mar 24, 2026
Initiates: Overweight
Price Target: $24
Current: $13.75
Upside: +74.55%
CRISPR Therapeutics AG
Mar 17, 2026
Reiterates: Overweight
Price Target: $105 → $110
Current: $49.51
Upside: +122.18%
Capricor Therapeutics
Mar 13, 2026
Reiterates: Overweight
Price Target: $45 → $58
Current: $32.11
Upside: +80.63%
ImmunityBio
Mar 4, 2026
Reiterates: Overweight
Price Target: $7 → $12
Current: $7.30
Upside: +64.38%
Cardiff Oncology
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $6
Current: $1.58
Upside: +279.75%
Arvinas
Feb 25, 2026
Reiterates: Overweight
Price Target: $16 → $20
Current: $10.85
Upside: +84.33%
Moderna
Feb 23, 2026
Maintains: Overweight
Price Target: $63 → $69
Current: $49.20
Upside: +40.24%
Century Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $2 → $4
Current: $2.13
Upside: +87.79%
Monte Rosa Therapeutics
Jan 14, 2026
Reiterates: Overweight
Price Target: $28 → $37
Current: $17.09
Upside: +116.50%
Jan 13, 2026
Reiterates: Overweight
Price Target: $100 → $110
Current: $61.03
Upside: +80.24%
Jan 9, 2026
Maintains: Overweight
Price Target: $6 → $8
Current: $1.52
Upside: +426.32%
Dec 9, 2025
Reiterates: Overweight
Price Target: $98 → $125
Current: $85.40
Upside: +46.37%
Dec 8, 2025
Reiterates: Overweight
Price Target: $16 → $23
Current: $8.04
Upside: +186.07%
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $1.13
Upside: +430.97%
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $318.85
Upside: +53.36%
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $4.47
Upside: +168.46%
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $10.72
Upside: +39.93%
Jun 16, 2025
Upgrades: Overweight
Price Target: $20
Current: $23.78
Upside: -15.90%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.54
Upside: +354.55%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $18.84
Upside: +154.78%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $14.81
Upside: +62.05%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $19.14
Upside: +307.52%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $12.81
Upside: +134.19%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $1.59
Upside: +3,988.05%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $0.70
Upside: +2,765.33%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.14
Upside: +163.16%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.18
Upside: +1,567.59%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.22
Upside: +391.80%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.38
Upside: +262.32%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $4.24
Upside: +2,022.64%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $9.27
Upside: +1,841.75%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $15.51
Upside: +183.69%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $5.05
Upside: +632.67%
May 13, 2022
Maintains: Overweight
Price Target: $40,439,520 → $11,721,600
Current: $4.17
Upside: +281,093,425.18%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $746.75
Upside: -52.59%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $438.71
Upside: -26.38%
May 7, 2021
Downgrades: Neutral
Price Target: $80 → $25
Current: $10.20
Upside: +145.10%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $43.88
Upside: -17.96%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.32
Upside: +1,793.94%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.55
Upside: +27,347.39%
Dec 11, 2017
Initiates: Overweight
Price Target: $13,800
Current: $0.36
Upside: +3,877,393.68%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $761.85
Upside: -
Apr 15, 2013
Maintains: Neutral
Price Target: $882 → $1,064
Current: $11.87
Upside: +8,863.77%